Indications and uses
Revesta is indicated for dietary management of patients with unique nutritional needs requiring increased folate levels, Vitamin D deficiency or are in need of Vitamin D supplementation and other nutritional supplementation.
Revesta is indicated for dietary management of patients with unique nutritional needs requiring increased folate levels, Vitamin D deficiency or are in need of Vitamin D supplementation and other nutritional supplementation.
Take one capsule daily or as directed by a physician.
Store at controlled room temperature 15°-30°C (59°F-86°F). Keep in cool dry place. Call your doctor about side effects. You may report side effects to FDA at 1-800-FDA-1088 . KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN.
Revesta is an orally administered prescription Vitamin for the dietary management of patients with unique nutritional needs requiring increased folate levels, Vitamin D supplementation due to Vitamin D deficiency and other nutritional supplementation.
Revesta should be administered under the supervision of a licensed medical practitioner.
Vitamin D3 (cholecalciferol) is a white, crystalline powder, very soluble in water, with the following structural formula:
Each capsule contains:
Folic Acid: 1mg, Vitamin D3 (Cholecalciferol): 5750IU
Each capsule contains the following inactive ingredients: soybean oil, gelatin (bovine), yellow wax, glycerin, deionized water, lecithin, titanium dioxide, FD&C Blue #1.
Revesta is indicated for dietary management of patients with unique nutritional needs requiring increased folate levels, Vitamin D deficiency or are in need of Vitamin D supplementation and other nutritional supplementation.
The in vivo synthesis of the major biologically active metabolites of vitamin D occurs in two steps. The first hydroxylation of ergocalciferol takes place in the liver (to 25-hydroxyvitamin D) and the second in the kidneys (to 1,25-dihydroxyvitamin D). Vitamin D metabolites promote the active absorption of calcium and phosphorus by the small intestine, thus elevating serum calcium and phosphate levels sufficiently to permit bone mineralization. Vitamin D metabolites also mobilize calcium and phosphate from bone and probably increase the reabsorption of calcium and perhaps also of phosphate by the renal tubules.
There is a time lag of 10 to 24 hours between the administration of vitamin D and the initiation of its action in the body due to the necessity of synthesis of the active metabolites in the liver and kidneys. Parathyroid hormone is responsible for the regulation of this metabolism in the kidneys.
This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. Revesta is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D.
Tell your doctor if you have: kidney problems, thyroid disease. This medication should be used as directed during pregnancy or while breast-feeding. Consult your doctor about the risks and benefits.
Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B12 is deficient. Folic acid in doses above 1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress.
This medication is generally well tolerated. Notify your doctor if you experience: nausea, loss of appetite, vomiting, stomach cramps, dry mouth, increased thirst, increased urination, muscle or bone pain,headache, weakness, weight loss, dizziness. If you notice other effects not listed above, contact your doctor or pharmacist.
Take one capsule daily or as directed by a physician.
Revesta capsules are supplied as blue capsules imprinted in white ink “330”, dispensed in HDPE plastic bottles of 30ct.
Store at controlled room temperature 15°-30°C (59°F-86°F). Keep in cool dry place.
Call your doctor about side effects. You may report side effects to FDA at 1-800-FDA-1088.
KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN.
Reserved for Professional Recommendation
All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product. This product may be administered only under a physician’s supervision. There are no implied or explicit claims on therapeutic equivalence.
Rx Only
Reserved for Professional Recommendation
All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product. This product may be administered only under a physician’s supervision. There are no implied or explicit claims on therapeutic equivalence.
Manufactured for:Sterling Knight Pharmaceuticals, LLC
Ripley, MS 38663
Rev. 1114-1
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1601102 | cholecalciferol 5750 UNT / folic acid 1 MG Oral Capsule | PSN | 9 |
| 1601102 | cholecalciferol 5750 UNT / folic acid 1 MG Oral Capsule | SCD | 9 |
| 1601102 | cholecalciferol 5750 UNT / folate 1 MG Oral Capsule | SY | 9 |
| 1601102 | vitamin D3 5750 UNT / folic acid 1 MG Oral Capsule | SY | 9 |
| Class | Version | Type | Effective |
|---|---|---|---|
| CHOLECALCIFEROL Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| baf7f49c-75b6-496b-a00e-8e766a8e4f03 | Product name | 1 | 20210127 |
| 91c62db0-0295-c81c-d10a-0856c259edd6 | Product name | 2 | 20200428 |
| d32bc2b8-0bb7-2216-87aa-24639646e202 | Product name | 3 | 20190619 |
| ebc62596-fc97-4d03-9483-7ba095d25db7 | Product name | 1 | 20151210 |
| 0ca1d589-929b-4b33-bc5b-1d84abdafa6a | Product name | 1 | 20150324 |
| fc363c46-397b-4476-ac0f-70e43e8e4592 | Product name | 1 | 20150324 |
| 60c52429-fcef-eb54-2387-43bc9e4f296b | Product name | 1 | 20140508 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 69336-330-30 | 2021-01-29 | C162847 | 48780-1 | ba0f9c33-1680-a910-e053-dadaa90a0b85 | Revesta Cholecalciferol Capsules Rx Only |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 69336-330-30 | Revesta | 30 in 1 BOTTLE, PLASTIC | CAPSULE | 30 | 9 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 69336-330-30 | EA - Each | 69336-330 | fcca2333-1f03-4e44-8e35-0391a25d8949 | 1 | 2016-11-08 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 69336-330 | 69336-330-30 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| WATER | 059QF0KO0R | IACT |
| SOYBEAN OIL | 241ATL177A | IACT |
| YELLOW WAX | 2ZA36H0S2V | IACT |
| LECITHIN, SOYBEAN | 1DI56QDM62 | IACT |
| FD&C BLUE NO. 1 | H3R47K3TBD | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| TITANIUM DIOXIDE | 15FIX9V2JP | IACT |
| GELATIN | 2G86QN327L | IACT |
| CHOLECALCIFEROL | 1C6V77QF41 | ACTIB |
| FOLIC ACID | 935E97BOY8 | ACTIB |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 99d751a9-5482-0c33-e053-2a95a90a1d82 | e5567a73-bf94-4bad-ade6-ddef18c8af04 | 2019-12-16 | Warnings, Adverse reactions | 99d751a9-5482-0c33-e053-2a95a90a1d82 e5567a73-bf94-4bad-ade6-ddef18c8af04 |
Adverse event summaries are temporarily unavailable. Other product information remains available.